CP-675,206 (Tremelimumab) [clinicaltrials_resource:81332eb078db8d8bdfde36a7445a7abd]
CP-675,206 (Tremelimumab) [clinicaltrials_resource:81332eb078db8d8bdfde36a7445a7abd]
Bio2RDF identifier
81332eb078db8d8bdfde36a7445a7abd
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:81332eb078db8d8bdfde36a7445a7abd
arm group [clinicaltrials_vocabulary:arm-group]
intervention desc [clinicaltrials_vocabulary:intervention-desc]
15 mg/kg IV every 3 months as long as required
intervention name [clinicaltrials_vocabulary:intervention-name]
CP-675,206 (Tremelimumab)
other name [clinicaltrials_vocabulary:other-name]
anti-CTLA4 human monoclonal antibody
identifier
clinicaltrials_resource:81332eb078db8d8bdfde36a7445a7abd
title
CP-675,206 (Tremelimumab)
@en
type
label
CP-675,206 (Tremelimumab) [clinicaltrials_resource:81332eb078db8d8bdfde36a7445a7abd]
@en